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Abstract
Exacerbations are a major cause of morbidity and mortality in chronic obstructive pulmonary
disease. Exacerbations can be of bacterial, viral or mixed etiology, with bacteria involved in 50% of
exacerbations. Consequently, current management of exacerbations frequently involves the use of
antibiotics. The paper by Puhan et al published this month in BMC Medicine examines the benefit of
antibiotics in placebo-controlled trials in mild to moderate outpatient exacerbations. The authors
use a meta-analytic approach and rightly conclude that more trials are needed in this area.
However, the heterogeneity of chronic obstructive pulmonary disease patients and exacerbations
and the limited end-points in past trials do not allow firm conclusions to be drawn about antibiotic
use in outpatient exacerbations based on this meta-analysis. Future trials need to take into account
this heterogeneity as well as incorporate novel end-points to address this important issue.
Background
Bronchitis is among the most common reasons for antibi-
otic prescription worldwide. This diagnosis includes two
distinct entities, acute bronchitis in the absence of under-
lying lung disease and acute exacerbations of chronic
bronchitis or chronic obstructive pulmonary disease
(COPD). Acute bronchitis is predominantly a viral disease
with good evidence that antibiotics are not of benefit in its
management. Exacerbations of COPD, on the other hand,
can be of bacterial, viral or mixed etiology, with bacterial
infection currently estimated to contribute up to 50% of
exacerbations. Furthermore, in contrast to acute bronchi-
tis, these exacerbation episodes are not benign events, as
they have consequences ranging from days lost from
work, deterioration of health status, progression of air-
flow obstruction and even death. Therefore, appropriate
management of COPD exacerbations is crucial.
Antibiotics are often used in the management of COPD
exacerbations. It is estimated that more than 80% of
COPD exacerbations are treated on an outpatient basis,
which can be regarded as mild to moderate exacerbations.
The article published by Puhan et al this month in BMC
Medicine makes the argument that there is a lack of evi-
dence for antibiotic benefit in mild to moderate exacerba-
tions of COPD and that additional placebo-controlled
trials are required [1]. Their argument is based on a meta-
analytic approach where they identified five placebo-con-
trolled randomized trials in the literature, which were
confined to 'mild to moderate' exacerbations of COPD.
With this approach, although all but one of the trials favor
antibiotics, the combined odds ratio is not statistically sig-
nificant.
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erroneous, their approach to this question highlights a
number of issues that make it difficult to resolve this argu-
ment; these include the heterogeneity of exacerbations,
patients and antibiotics in these trials. Another major
issue is the acceptance of the results of these trials without
critically examining the limitations of the end-points used
in these studies. The 'devil is in the details' in these trials,
and these details are often overlooked in a meta-analytic
approach.
Severity of exacerbations
Puhan et al have grouped together mild and moderate
exacerbations based on the site of treatment, that is, out-
patient treatment. This classification is clearly very broad
as the site of care will vary among countries and health-
care systems as well as with patient and physician prefer-
ences. Furthermore, over time, changes in healthcare
delivery and results of outcome studies can change the site
of care for the same severity of exacerbation. A 40-year-old
smoker without underlying airway obstruction, infre-
quent exacerbations and free of comorbid conditions
would have been included as a 'mild to moderate' exacer-
bation. On the other hand, a patient with severe COPD,
frequent exacerbations and comorbid conditions who
does not require hospitalization would also be classified
as a 'mild to moderate exacerbation'. In the former
patient, it is possible that host immunity can adequately
deal with the infection and the exacerbation will sponta-
neously resolve. In the latter patient, such resolution is
less likely and complications are more frequent. Grouping
these patients together can lead to confusing and contra-
dictory results.
The severity of an exacerbation is a complicated concept,
constituted by at least two factors, the severity of the
underlying COPD and the acute change induced by the
exacerbation itself. Therefore, a patient with severe under-
lying COPD will have significant clinical consequences
from a relatively small change from the baseline state,
while a patient with mild COPD will tolerate a much
larger change in symptoms and lung function. It is evident
that we need more objective measures of severity of exac-
erbations. Ongoing developmental efforts in patient-
reported outcomes and biomarkers should provide us
with such tools in the future, and allow for trials to be
pooled as attempted by Puhan et al here.
Heterogeneity of COPD
COPD is a heterogeneous disease. Outcomes of exacerba-
tions worsen and antibiotic benefit in exacerbations
increases with worsening underlying airflow obstruction,
in frequent 'exacerbators' and with comorbid conditions
[2,3]. This is likely related to a greater proportion of bac-
terial etiology and more severe local immunocompromise
in these patients.
In grouping together the trials in their analysis, Puhan et
al have pooled together patients who are very heterogene-
ous with respect to their COPD disease and, therefore,
could not discern a beneficial effect of antibiotics. This is
best illustrated by comparing the patient populations of
two trials included in their analysis; the trial conducted by
Anthonisen et al [4], which showed a significant benefit of
antibiotics, and the trial conducted by Sachs et al [5],
which failed to show benefit (Table 1). (Note: In the
Anthonisen study [4], there was significant benefit with
antibiotics when all 362 exacerbations were considered.
For their analysis, Puhan et al chose to consider only the
first exacerbation from the 116 patients in the study, with
considerable alteration in the results). As is evident from
this comparison, Sachs et al [5] included patients of
younger age, mild underlying disease and asthma. Not
surprisingly, only 11% of their exacerbations were associ-
ated with a positive bacterial culture, rather than the usual
40% to 50%. Not surprisingly, antibiotics were of no ben-
efit in this study and, in their placebo arm, there was a
93% resolution rate compared with 55% in the
Anthonisen study [4].
All antibiotics are not the same
An additional consideration is the spectrum of the differ-
ent antibiotics used to treat COPD. In this study, the
authors tended to treat all antibiotics as equivalent when
Table 1: Comparison of patients included in two placebo-controlled trials of antibiotics in acute exacerbation of chronic bronchitis
Characteristic Anthonisen Sachs
N 362 71
Age in years (mean ± standard deviation) 67.3 ± 9 51.7 ± 16.3
Minimum age for inclusion in years 35 18
Smoking in pack-years (mean ± standard deviation) 39.9 ± 28.9 16.5 (0.15–77)
Smokers (% of subjects) 93.6 69.1
Asthmatics Excluded Included
Forced expiratory volume1 (% predicted) 33.9 ± 3.7 NA
Peak expiratory flow (liter/minute) 227.5 ± 96.1 285.3 ± 99.2
Data from Anthonisen et al [4] and Sachs et al [5].Page 2 of 4
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in their antimicrobial spectrum, pharmacokinetic/phar-
macodynamic profiles and ability to penetrate respiratory
tissues. Recent studies indeed show differences in clinical
outcomes among antibiotics used in exacerbations. A
recent meta-analysis of antibiotic comparison trials,
which were quite homogenous, demonstrated that amox-
icillin results in suboptimal outcomes with increased risk
of clinical failures in COPD [6]. This has been seen partic-
ularly since the early 1990s, when resistance emerged to
this agent. Interestingly, two trials (Sachs et al [5] and Jor-
gensen et al [7]) included in the analysis by Puhan et al,
both not showing a significant benefit of antibiotics, used
amoxicillin and were conducted in the 1990s. Two trials
comparing fluoroquinolones with non-fluoroquinolone
antibiotics, the GLOBE and MOSAIC trials, showed more
complete clinical resolution of exacerbations and a pro-
longed time to the next exacerbation [8,9].
End-points in exacerbation trials
Analysis of any study should critically examine if its end-
points were adequate to demonstrate the potential bene-
fits of the intervention being tested and were clinically rel-
evant. Unfortunately, in the studies evaluated by Puhan et
al, as well as in the vast majority of antibiotic comparison
trials in exacerbations of COPD, end-points used favor the
demonstration of equivalence rather than differences
among the arms (Table 2) [10]. Partly, this is the result of
mandates (now obsolete) by regulatory agencies, such as
the Food and Drug Administration (FDA). These end-
points assessed at 2 to 3 weeks after the onset of symp-
toms and the initiation of therapy miss differences in ther-
apeutic effect earlier during the course of treatment. In
addition, these end-points have minimal relevance to
clinical practice. In clinical practice, most physicians and
patients expect clinical improvement in their exacerbation
at 3 to 5 days after initiation of treatment. In fact, with
insufficient improvement in that timeframe, therapy is
often altered or expanded. Allegra et al [11] did conduct a
placebo-controlled trial where they used a 5-day time-
point, showing a substantial benefit of antibiotics, which
was excluded from the analysis by Puhan et al.
The adequacy of the traditional goals of treatment of an
exacerbation, recovery to baseline clinical status and the
prevention of complications, are being questioned
because of several new observations. These include reali-
zation of the importance of exacerbations in the course of
COPD, the role of infection in exacerbations, the high
rates of relapse with an adequate initial clinical response,
and the role played by chronic infection in the pathogen-
esis of COPD. Today, confining our goal in the treatment
of COPD exacerbations to short-term resolution of symp-
toms would be analogous to treating acute myocardial
infarction with the only aim being resolution of chest
pain.
Table 3 lists several other important goals of treatment,
both clinical and biological, that should be considered
[12]. In fact, the FDA wants precise symptom measure-
ment with a patient-reported outcome measure as the
major end-point of future studies of antibiotics in exacer-
bations. Practical application of the biological goals of
treatment of exacerbations should be feasible in the future
with ongoing development of simple, rapid and reliable
measurements of inflammation and infection.
Conclusion
Recent American College of Physicians/American College
of Chest Physicians guidelines for COPD exacerbations
state for future research priorities: 'Our first research
objectives must include untangling the questions sur-
rounding selection of patients for antibiotic and corticos-
teroid treatment, identifying optimal dosing and
durations for these agents, and determining the degree to
which broad- and narrow-spectrum antibiotics have simi-
lar efficacy' [12]. Undoubtedly, as stated by Puhan et al,
we need to enlarge our evidence base for the treatment of
Table 2: Limitations of published placebo-controlled antibiotic trials in acute exacerbations of chronic obstructive pulmonary disease
Limitation of study design Potential consequences
Small number of subjects Type 2 error
Subjects with mild or no underlying chronic obstructive pulmonary 
disease included
Diminished overall perceived efficacy of antibiotics
Non-bacterial exacerbations included Type 2 error
End-points compared at 3 weeks after onset Spontaneous resolution mitigates differences between arms
Clinically irrelevant as most decisions about antibiotic efficacy are made 
earlier
Speed of resolution not measured Clinically relevant end-point not assessed
Lack of long-term follow-up Time to next exacerbation not assessed
Antibiotic resistance to agents with limited in vitro antimicrobial efficacy Diminished overall perceived efficacy of antibiotics
Poor penetration of antibiotics into respiratory tissues Diminished overall perceived efficacy of antibiotics
Concurrent therapy not controlled Undetected bias in use of concurrent therapy
Reproduced with permission from Sethi [10].Page 3 of 4
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highlighted in this commentary, these trials should use
contemporary end-points so that we do not miss impor-
tant, clinically relevant benefits of antibiotics, not
assessed by traditional end-points.
Until such studies are completed, how should we treat
outpatient 'mild to moderate' exacerbations? Lack of evi-
dence is not the same as lack of efficacy. As discussed
above, the heterogeneity of severity and patients among
outpatient exacerbations demonstrates that grouping
them all together is perhaps not the best course of action.
'Moderate' exacerbations, such as those included in the
Anthonisen [4] trial, should receive antibiotics. The
choice of initial antibiotics in these patients should be
based on a 'risk stratification' approach. 'Mild' exacerba-
tions, such as those included in the Sachs [5] trial, likely
do not need antibiotics, especially if they do not have
purulent sputum. These are the patients that should be
included in placebo-controlled trials with contemporary
end-points.
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Table 3: Proposed goals of treatment of chronic obstructive pulmonary disease exacerbation
Goals Comments
Clinical
Clinical resolution to baseline Needs baseline assessment prior to exacerbation onset for comparison
Prevention of relapse Relapse within 30 days is quite frequent
Increasing exacerbation-free interval Needs long-term follow-up after treatment
Faster resolution of symptoms Needs validated symptom assessment tools
Preservation of health-related quality of life Sustained decrements seen after exacerbations
Biological
Bacterial eradication Often presumed in usual antibiotic comparison studies
Resolution of airway inflammation Shown to be incomplete if bacteria persist
Resolution of systemic inflammation Persistence of systemic inflammation predicts early relapse
Restoration of lung function to baseline Incomplete recovery is seen in significant proportion
Preservation of lung function Needs long-term studiesPage 4 of 4
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